- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to this study, over the next five years the Chemotherapy-induced Nausea and Vomiting Drugs market will register a 4.6%% CAGR in terms of revenue, the global market size will reach $ 1944.4 million by 2025, from $ 1624.5 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy-induced Nausea and Vomiting Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy-induced Nausea and Vomiting Drugs market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Chemotherapy-induced Nausea and Vomiting Drugs, covering the supply chain analysis, impact assessment to the Chemotherapy-induced Nausea and Vomiting Drugs market size growth rate in several scenarios, and the measures to be undertaken by Chemotherapy-induced Nausea and Vomiting Drugs companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Merck
Tesaro
Eisai
Qilu Pharma
Teva
Mundipharma
Roche
Novartis
Mylan
Heron Therapeutics
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Chemotherapy-induced Nausea and Vomiting Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Chemotherapy-induced Nausea and Vomiting Drugs market by identifying its various subsegments.
Focuses on the key global Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chemotherapy-induced Nausea and Vomiting Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Chemotherapy-induced Nausea and Vomiting Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2015-2025
2.1.2 Chemotherapy-induced Nausea and Vomiting Drugs Consumption CAGR by Region
2.2 Chemotherapy-induced Nausea and Vomiting Drugs Segment by Type
2.2.1 5-HT3 Inhibitors
2.2.2 NK1 Inhibitors
2.2.3 Other
2.3 Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type
2.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Type (2015-2020)
2.4 Chemotherapy-induced Nausea and Vomiting Drugs Segment by Application
2.4.1 Highly Emetogenic Chemotherapy
2.4.2 Moderately Emetogenic Chemotherapy
2.4.3 Low Emetogenic Chemotherapy
2.4.4 Other
2.5 Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application
2.5.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Type (2015-2020)
3 Global Chemotherapy-induced Nausea and Vomiting Drugs by Company
3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Company
3.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Company (2018-2020)
3.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Company (2018-2020)
3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company
3.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (2018-2020)
3.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Company
3.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Chemotherapy-induced Nausea and Vomiting Drugs by Regions
4.1 Chemotherapy-induced Nausea and Vomiting Drugs by Regions
4.2 Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth
4.3 APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth
4.4 Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth
4.5 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth
5 Americas
5.1 Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries
5.1.1 Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020)
5.2 Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type
5.3 Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Regions
6.1.1 APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Chemotherapy-induced Nausea and Vomiting Drugs Value by Regions (2015-2020)
6.2 APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type
6.3 APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs by Countries
7.1.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020)
7.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type
7.3 Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs by Countries
8.1.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type
8.3 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Chemotherapy-induced Nausea and Vomiting Drugs Distributors
10.3 Chemotherapy-induced Nausea and Vomiting Drugs Customer
11 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Forecast
11.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Forecast (2021-2025)
11.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Forecast by Regions
11.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Forecast by Regions (2021-2025)
11.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Chemotherapy-induced Nausea and Vomiting Drugs Forecast by Type
11.8 Global Chemotherapy-induced Nausea and Vomiting Drugs Forecast by Application
12 Key Players Analysis
12.1 Merck
12.1.1 Company Information
12.1.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.1.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Merck Latest Developments
12.2 Tesaro
12.2.1 Company Information
12.2.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.2.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Tesaro Latest Developments
12.3 Eisai
12.3.1 Company Information
12.3.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.3.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Eisai Latest Developments
12.4 Qilu Pharma
12.4.1 Company Information
12.4.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.4.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Qilu Pharma Latest Developments
12.5 Teva
12.5.1 Company Information
12.5.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.5.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Teva Latest Developments
12.6 Mundipharma
12.6.1 Company Information
12.6.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.6.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Mundipharma Latest Developments
12.7 Roche
12.7.1 Company Information
12.7.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.7.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Roche Latest Developments
12.8 Novartis
12.8.1 Company Information
12.8.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.8.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Novartis Latest Developments
12.9 Mylan
12.9.1 Company Information
12.9.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.9.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Mylan Latest Developments
12.10 Heron Therapeutics
12.10.1 Company Information
12.10.2 Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
12.10.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Heron Therapeutics Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Chemotherapy-induced Nausea and Vomiting Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of 5-HT3 Inhibitors
Table 5. Major Players of NK1 Inhibitors
Table 6. Major Players of Other
Table 7. Global Consumption Sales by Type (2015-2020)
Table 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Table 9. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2015-2020) ($ million)
Table 10. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 11. Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Type (2015-2020)
Table 12. Global Consumption Sales by Application (2015-2020)
Table 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Table 14. Global Chemotherapy-induced Nausea and Vomiting Drugs Value by Application (2015-2020)
Table 15. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Application (2015-2020)
Table 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Application (2015-2020)
Table 17. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Company (2017-2019) (K Units)
Table 18. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Company (2017-2019)
Table 19. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (2017-2019) ($ Millions)
Table 20. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company (2017-2019)
Table 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Company (2017-2019)
Table 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 23. Players Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
Table 24. Chemotherapy-induced Nausea and Vomiting Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Regions 2015-2020 (K Units)
Table 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Regions 2015-2020
Table 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Value by Regions 2015-2020 ($ Millions)
Table 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Regions 2015-2020
Table 29. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020) (K Units)
Table 30. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries (2015-2020)
Table 31. Americas Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020) ($ Millions)
Table 32. Americas Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries (2015-2020)
Table 33. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type (2015-2020) (K Units)
Table 34. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Table 35. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application (2015-2020) (K Units)
Table 36. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Table 37. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Regions (2015-2020) (K Units)
Table 38. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Regions (2015-2020)
Table 39. APAC Chemotherapy-induced Nausea and Vomiting Drugs Value by Regions (2015-2020) ($ Millions)
Table 40. APAC Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Regions (2015-2020)
Table 41. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type (2015-2020) (K Units)
Table 42. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Table 43. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application (2015-2020) (K Units)
Table 44. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Table 45. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020) (K Units)
Table 46. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries (2015-2020)
Table 47. Europe Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020) ($ Millions)
Table 48. Europe Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries (2015-2020)
Table 49. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type (2015-2020) (K Units)
Table 50. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Table 51. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application (2015-2020) (K Units)
Table 52. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Table 53. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Countries (2015-2020) (K Units)
Table 54. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries (2015-2020)
Table 55. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value by Countries (2015-2020) ($ Millions)
Table 56. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Type (2015-2020) (K Units)
Table 58. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Table 59. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption by Application (2015-2020) (K Units)
Table 60. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Table 61. Chemotherapy-induced Nausea and Vomiting Drugs Distributors List
Table 62. Chemotherapy-induced Nausea and Vomiting Drugs Customer List
Table 63. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 64. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Forecast by Regions
Table 65. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 66. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share Forecast by Regions
Table 67. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 68. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 69. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 70. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share Forecast by Type (2021-2025)
Table 71. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 72. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 73. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 74. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share Forecast by Application (2021-2025)
Table 75. Merck Product Offered
Table 76. Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 77. Merck Main Business
Table 78. Merck Latest Developments
Table 79. Merck Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Tesaro Product Offered
Table 81. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 82. Tesaro Main Business
Table 83. Tesaro Latest Developments
Table 84. Tesaro Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Eisai Product Offered
Table 86. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 87. Eisai Main Business
Table 88. Eisai Latest Developments
Table 89. Eisai Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Qilu Pharma Product Offered
Table 91. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 92. Qilu Pharma Main Business
Table 93. Qilu Pharma Latest Developments
Table 94. Qilu Pharma Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Teva Product Offered
Table 96. Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 97. Teva Main Business
Table 98. Teva Latest Developments
Table 99. Teva Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Mundipharma Product Offered
Table 101. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 102. Mundipharma Main Business
Table 103. Mundipharma Latest Developments
Table 104. Mundipharma Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Roche Product Offered
Table 106. Roche Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Roche Main Business
Table 108. Roche Latest Developments
Table 109. Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 110. Novartis Product Offered
Table 111. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 112. Novartis Main Business
Table 113. Novartis Latest Developments
Table 114. Novartis Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan Product Offered
Table 116. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Mylan Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Heron Therapeutics Product Offered
Table 121. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 122. Heron Therapeutics Main Business
Table 123. Heron Therapeutics Latest Developments
Table 124. Heron Therapeutics Basic Information, Company Total Revenue (in $ million), Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Chemotherapy-induced Nausea and Vomiting Drugs
Figure 2. Chemotherapy-induced Nausea and Vomiting Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of 5-HT3 Inhibitors
Figure 7. Product Picture of NK1 Inhibitors
Figure 8. Product Picture of Other
Figure 9. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type (2015-2020)
Figure 10. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Type (2015-2020)
Figure 11. Chemotherapy-induced Nausea and Vomiting Drugs Consumed in Highly Emetogenic Chemotherapy
Figure 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Highly Emetogenic Chemotherapy (2015-2020) (K Units)
Figure 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Highly Emetogenic Chemotherapy (2015-2020) ($ Millions)
Figure 14. Chemotherapy-induced Nausea and Vomiting Drugs Consumed in Moderately Emetogenic Chemotherapy
Figure 15. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Moderately Emetogenic Chemotherapy (2015-2020) (K Units)
Figure 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Moderately Emetogenic Chemotherapy (2015-2020) ($ Millions)
Figure 17. Chemotherapy-induced Nausea and Vomiting Drugs Consumed in Low Emetogenic Chemotherapy
Figure 18. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Low Emetogenic Chemotherapy (2015-2020) (K Units)
Figure 19. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Low Emetogenic Chemotherapy (2015-2020) ($ Millions)
Figure 20. Chemotherapy-induced Nausea and Vomiting Drugs Consumed in Other
Figure 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Other (2015-2020) (K Units)
Figure 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Other (2015-2020) ($ Millions)
Figure 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application (2015-2020)
Figure 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Application (2015-2020)
Figure 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Company in 2017
Figure 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Company in 2019
Figure 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company in 2017
Figure 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company in 2019
Figure 29. Global Chemotherapy-induced Nausea and Vomiting Drugs Sale Price by Company in 2019
Figure 30. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Regions 2015-2020
Figure 31. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Regions 2015-2020
Figure 32. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2015-2020 (K Units)
Figure 33. Americas Chemotherapy-induced Nausea and Vomiting Drugs Value 2015-2020 ($ Millions)
Figure 34. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2015-2020 (K Units)
Figure 35. APAC Chemotherapy-induced Nausea and Vomiting Drugs Value 2015-2020 ($ Millions)
Figure 36. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2015-2020 (K Units)
Figure 37. Europe Chemotherapy-induced Nausea and Vomiting Drugs Value 2015-2020 ($ Millions)
Figure 38. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2015-2020 (K Units)
Figure 39. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value 2015-2020 ($ Millions)
Figure 40. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries in 2019
Figure 41. Americas Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries in 2019
Figure 42. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type in 2019
Figure 43. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application in 2019
Figure 44. United States Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. United States Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. Canada Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 47. Canada Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 48. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 49. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 50. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries in 2019
Figure 51. APAC Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Regions in 2019
Figure 52. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type in 2019
Figure 53. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application in 2019
Figure 54. China Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. China Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Japan Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Japan Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. Korea Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. Korea Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. India Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 63. India Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Australia Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 65. Australia Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 66. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries in 2019
Figure 67. Europe Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries in 2019
Figure 68. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type in 2019
Figure 69. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application in 2019
Figure 70. Germany Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. Germany Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. France Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. France Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. UK Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. UK Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Italy Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 77. Italy Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 78. Russia Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 79. Russia Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 80. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Countries in 2019
Figure 81. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value Market Share by Countries in 2019
Figure 82. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Type in 2019
Figure 83. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Market Share by Application in 2019
Figure 84. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Israel Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. Israel Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 91. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 92. GCC Countries Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth 2015-2020 (K Units)
Figure 93. GCC Countries Chemotherapy-induced Nausea and Vomiting Drugs Value Growth 2015-2020 ($ Millions)
Figure 94. Global Chemotherapy-induced Nausea and Vomiting Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 95. Global Chemotherapy-induced Nausea and Vomiting Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 96. Americas Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 97. Americas Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 98. APAC Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 99. APAC Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 100. Europe Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 101. Europe Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 102. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 103. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 104. United States Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 105. United States Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 106. Canada Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 107. Canada Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 108. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 109. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 110. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 111. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 112. China Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 113. China Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 114. Japan Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 115. Japan Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 116. Korea Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 117. Korea Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 118. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 119. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 120. India Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 121. India Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 122. Australia Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 123. Australia Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 124. Germany Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 125. Germany Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 126. France Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 127. France Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 128. UK Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 129. UK Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 130. Italy Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 131. Italy Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 132. Russia Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 133. Russia Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 134. Spain Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 135. Spain Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 136. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 137. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 138. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 139. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 140. Israel Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 141. Israel Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 142. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 143. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 144. GCC Countries Chemotherapy-induced Nausea and Vomiting Drugs Consumption 2021-2025 (K Units)
Figure 145. GCC Countries Chemotherapy-induced Nausea and Vomiting Drugs Value 2021-2025 ($ Millions)
Figure 146. Merck Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 147. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 148. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 149. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 150. Teva Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 151. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 152. Roche Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 153. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 154. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Figure 155. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Market Share (2018-2020)
Please feel free to write an email to us or to use our electronic ticketing system.
